TORONTO, April 1, 2026
Quantum BioPharma Ltd. announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead candidate Lucid-MS (Lucid-21-302), marking a major milestone toward initiating a Phase 2 clinical trial for multiple sclerosis (MS). The IND submission includes comprehensive preclinical pharmacology, toxicology, and manufacturing data, positioning the company to advance its first-in-class neuroprotective therapy targeting demyelination, a key driver of disease progression in MS.
IND Submission Marks Key Regulatory Milestone
The IND submission represents a critical regulatory step enabling human clinical trials under FDA oversight, demonstrating Quantum BioPharma’s commitment to GxP-compliant drug development. The application integrates nonclinical safety data, pharmacological validation, and Chemistry, Manufacturing, and Controls (CMC) information, all essential for regulatory evaluation.
Subject to FDA clearance, the company plans to initiate its Phase 2 clinical trial in Q2 2026, with interim data expected by Q4 2026, reflecting a structured and accelerated clinical development timeline. This milestone underscores the transition from early-stage research to advanced clinical validation, a pivotal phase in pharmaceutical innovation.
First-in-Class Approach Targets Demyelination in MS
Advertisement
Lucid-MS introduces a novel therapeutic mechanism focused on inhibiting demyelination, addressing the underlying neurodegenerative process in multiple sclerosis rather than solely modulating immune response. This innovative approach differentiates Lucid-MS from existing therapies, which primarily target inflammation without directly addressing neuronal damage.
In prior Phase 1 clinical trials, Lucid-MS demonstrated a favorable safety profile and strong tolerability, providing a solid foundation for further clinical investigation. The upcoming Phase 2 trial will evaluate efficacy, safety, and tolerability in MS patients, aiming to validate its potential as a disease-modifying therapy with neuroprotective benefits.
Strong Market Potential and Strategic Growth
Multiple sclerosis affects approximately 2.8 million people globally, representing a significant unmet medical need and expanding therapeutic market. The global MS treatment market is projected to exceed $38 billion by 2030, driven by increasing diagnosis rates and demand for innovative therapies. Quantum BioPharma’s strategy focuses on capturing this opportunity through differentiated scientific innovation, targeting mechanisms that directly impact disease progression.
The company’s diversified business platform, combining clinical-stage drug development with additional revenue-generating initiatives, supports sustained investment in research while advancing high-potential therapeutic programs. This strategic positioning enhances the company’s ability to deliver transformative treatments while maintaining long-term growth and shareholder value.
Advancing Drug Development Under cGxP Standards
From a compliance perspective, the IND submission highlights adherence to Good Laboratory Practice (GLP) through rigorous preclinical studies, Good Manufacturing Practice (GMP) via validated production processes, and Good Clinical Practice (GCP) as the program advances into Phase 2 trials.
The integration of these frameworks ensures data integrity, patient safety, and regulatory compliance, which are essential for successful drug development and future regulatory approvals. Lucid-MS represents a promising advancement in neurodegenerative disease treatment, reinforcing the importance of robust clinical governance and innovative therapeutic strategies in addressing complex medical conditions.
Source: Quantum BioPharma press release
